IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis

@article{Wood2011IBDVN,
  title={IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis},
  author={Natalie J. Wood},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  year={2011},
  volume={8},
  pages={3-3}
}
  • Natalie J. Wood
  • Published 6 January 2011
  • Medicine
  • Nature Reviews Gastroenterology &Hepatology
the potential of t-cell based therapies for severe ulcerative colitis has been called into question by the findings of an international, multicenter study. two open-label trials had indicated that visilizumab—a monoclonal antibody to the t-cell receptor CD3—was efficacious for intravenous corticosteroid-refractory ulcerative colitis. william sandborn and colleagues therefore conducted a 90-day randomized, double-blind, placebocontrolled trial of visilizumab in this patient population at a dose… 

Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities.

Based on extensive research over the last decade, besides the conventional therapy, there are several novel pathways and specific targets, on which focus new therapeutics that aim to correct genetic susceptibility or restore the immune dysregulation.

EPA- and DHA-derived resolvins' actions in inflammatory bowel disease.

References

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

Visilizumab at a dose of 5 μg/kg for two consecutive days was not effective for severe, corticosteroid-refractory UC and was associated with increased cardiac and vascular adverse events.